Tools
Candesartan
Indications
Candesartan is an oral angiotensin II receptor blocker available as the prodrug candesartan cilexetil, which undergoes hydrolysis in the gastrointestinal tract during absorption to its active metabolite. Candesartan is marketed under several brand names.[1]
Food and Drug Administration–Approved Indications
The US Food and Drug Administration (FDA) has approved candesartan for the treatment of hypertension and congestive heart failure with reduced ejection fraction (HFrEF), characterized by a left ventricular ejection fraction (LVEF) of ≤40%. The FDA approved candesartan in June 1998 for managing hypertension in adults. Clinical trial results showed that a daily dose of 8 mg of candesartan is as effective as 50 mg of losartan, another angiotensin II receptor blocker, or 10 to 20 mg of enalapril, an angiotensin-converting enzyme (ACE) inhibitor, in lowering blood pressure. In October 2009, the FDA extended the approval of candesartan to include the treatment of hypertension in adolescents and children aged 12 months or older.[2][3] The 2025 American Heart Association (AHA)/American College of Cardiology (ACC) guidelines endorse angiotensin receptor blockers (ARBs), such as candesartan, for the treatment of hypertension.[4]
Candesartan is often prescribed as monotherapy for managing hypertension and congestive heart failure. However, a combination formulation with low-dose hydrochlorothiazide, a thiazide diuretic, achieves synergistic antihypertensive effects.[5] In February 2005, the FDA approved candesartan for adults with congestive heart failure (New York Heart Association classes II through IV). Results from the placebo-controlled Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) trials demonstrated the efficacy of candesartan in specific subpopulations:
- Patients with an LVEF ≤40% who were intolerant of ACE inhibitors.
- Patients with an LVEF ≤40% who are currently taking ACE inhibitors.
- Patients with a LVEF >40%.[6]
Results from the CHARM trials demonstrated a reduction in cardiovascular mortality and hospitalizations due to congestive heart failure with either candesartan monotherapy or in combination with an ACE inhibitor. The 2022 ACC/AHA/Heart Failure Society of America (HFSA) guidelines endorse the use of candesartan for HFrEF. ARBs, such as candesartan, are crucial for guideline-directed medical therapy in congestive heart failure.[7][8]
Off-Label Uses
According to the 2023 ACC expert consensus, candesartan is also recommended for the treatment of congestive heart failure with preserved ejection fraction.[9][10] Candesartan is also used to treat cerebrovascular accident, diabetic nephropathy, left ventricular hypertrophy, and migraine headache.[11][12][13][14] Results from a recent phase 2 randomized controlled trial showed that administering 16 mg of candesartan was both effective and well-tolerated for the prevention of episodic migraine headache.[15][16] The American Headache Society endorses the use of candesartan for migraine prophylaxis; however, other possible causes should be considered, and an evaluation for focal neurological deficits should be performed.[17]
In patients with diabetes mellitus or hypertension who are not pregnant, the American Diabetes Association guidelines for chronic kidney disease recommend an ARB such as candesartan. Patients with moderately increased albuminuria (urinary albumin-to-creatinine ratio of 30-299 mg/g) or severely increased albuminuria (urinary albumin-to-creatinine ratio ≥300 mg/g) should receive an ARB.[18][19] The 2025 ACC/AHA/American College of Emergency Physicians/National Association of Emergency Medical Service Physicians/Society for Cardiovascular Angiography and Interventions guidelines recommend ARBs in patients with acute coronary syndrome. According to guidelines, patients with high-risk features (LVEF ≤40%, hypertension, diabetes mellitus, or anterior ST-segment elevation myocardial infarction) should receive an ACE inhibitor or an ARB to reduce all-cause death and major adverse cardiovascular events.[20]
Mechanism of Action
Register For Free And Read The Full Article
Search engine and full access to all medical articles- 10 free questions in your specialty
- Free CME/CE Activities
- Free daily question in your email
- Save favorite articles to your dashboard
- Emails offering discounts
Learn more about a Subscription to StatPearls Point-of-Care
Mechanism of Action
Similar to ACE inhibitors, such as enalapril, or direct renin inhibitors, such as aliskiren, candesartan interferes with the renin-angiotensin-aldosterone system. Typically, renin is released by renal juxtaglomerular cells in response to decreased renal perfusion pressure, increased sympathetic tone, or reduced delivery of sodium chloride to macula densa cells in the distal convoluted tubule of the nephron. The liver releases angiotensinogen, which is cleaved by renin into angiotensin I. Angiotensin I is converted into angiotensin II in the lungs by angiotensin-converting enzyme (ACE). Angiotensin II has several effects, including:
- Binding to type 1 angiotensin II receptor in vascular smooth muscle, leading to vasoconstriction and an increase in blood pressure.
- Constricting the efferent arteriole in the kidney, thereby preserving the glomerular filtration rate when renal perfusion decreases.
- Increasing the activity of the sodium-proton cotransporter in the proximal convoluted tubule of the nephron, which promotes the reabsorption of sodium, water, and bicarbonate.
- Stimulating the secretion of aldosterone from the zona glomerulosa of the adrenal cortex. Aldosterone acts on α-intercalated cells in the collecting duct to promote proton secretion and urine acidification, and on principal cells in the collecting duct to increase sodium reabsorption and potassium excretion. Ultimately, the net effect is water retention, increased intravascular volume, and elevated blood pressure.
- Promoting the release of antidiuretic hormone from the posterior pituitary gland, which acts on principal cells to increase water reabsorption via aquaporin-2 channels, thereby raising the intravascular volume and blood pressure.
Candesartan antagonizes the type 1 angiotensin II receptor, thereby blocking the effects of angiotensin II and reducing both blood pressure and fluid retention. Because candesartan blocks the binding of angiotensin II to its target receptor, its action is independent of the upstream biosynthesis of angiotensin II. Although a type 2 angiotensin II receptor also exists, it plays no role in maintaining blood pressure and normal hemodynamics. Furthermore, candesartan binds the type 1 angiotensin II receptor with 10 000-fold higher affinity than to the type 2 receptor.[1][3]
Pharmacokinetics
Absorption: Candesartan cilexetil undergoes rapid ester hydrolysis during absorption from the gastrointestinal tract, resulting in the conversion to candesartan. The bioavailability of candesartan is approximately 15%, and food does not affect absorption. The peak plasma concentration occurs within 3 to 4 hours.
Distribution: The mean volume of distribution of candesartan is 0.13 L/kg. Candesartan has high plasma protein binding (>99%). Results from animal studies have demonstrated that candesartan crosses the placental barrier and is distributed in the fetus.
Metabolism: Candesartan undergoes limited hepatic metabolism via the cytochrome P450 system. Consequently, the potential for drug-drug interactions with medications metabolized by this system is minimal. Candesartan undergoes minor hepatic metabolism by O-demethylation to an inactive metabolite.[21]
Excretion: The clearance of candesartan is 0.37 mL/min/kg, with a mean elimination half-life of approximately 9 hours. Repeated once-daily dosing does not lead to the accumulation of the drug or its inactive metabolite. Candesartan is predominantly excreted unchanged in urine and feces (via biliary excretion).[22]
Administration
Available Dosage Forms
Candesartan is administered orally and is available in tablet formulations of 4, 8, 16, and 32 mg. For patients who have difficulty swallowing, an oral suspension is available.[23]
Adult and Pediatric Dosage
Hypertension
- Adults and older patients should receive an initial dose of 16 mg/d. If volume depletion is present, the initial dose should be reduced to 8 mg/d. The usual maintenance dose ranges from 8 to 32 mg daily.[2][3]
- Children and adolescents aged 6 or older who weigh more than 50 kg should receive an initial dose of 8 to 16 mg/d. If the patient is volume-depleted, the initial dose should be reduced to 4 mg/d. The maintenance dose ranges from 4 to 32 mg/d.[2][3]
- Children and adolescents aged 6 or older who weigh less than 50 kg should receive an initial dose of 4 to 8 mg/d. If the patient is volume-depleted, the initial dose should be lowered to 2 mg/d. The dose ranges from 2 to 16 mg/d.
- Children aged 1 to 6 should receive an initial dose of 0.2 mg/kg/d as an oral suspension. If the patient is volume-depleted, the initial dose should be reduced to 0.1 mg/kg/d. The usual dose ranges from 0.05 to 0.4 mg/kg/d.
- Fixed dose combination contains candesartan 16 mg and hydrochlorothiazide 12.5 mg. The dose can be increased to candesartan 32 mg and hydrochlorothiazide 25 mg.[24]
Heart Failure with Reduced Ejection Fraction
- According to ACC/AHA/HFSA guidelines, candesartan is initiated at a dose of 4 to 8 mg/d for patients with HFrEF. The target dose of candesartan, 32 mg/d, is achieved by gradual titration every 2 weeks.[6][7]
Heart Failure with Preserved Ejection Fraction
- For guideline-directed medical therapy in patients with HFpEF, candesartan is initiated at the same dose (ie, 4-8 mg) and is gradually titrated to 32 mg/d as tolerated. Blood pressure should be controlled ideally to a systolic blood pressure of <130 mm Hg.[9]
Migraine Prophylaxis
- For migraine prevention, adults should receive 16 mg/d.[14]
Specific Patient Populations
Hepatic impairment: No dose adjustment of candesartan is necessary in patients with mild hepatic impairment. For moderate hepatic insufficiency, initial treatment with candesartan 8 mg daily is suggested. According to the American Association for the Study of Liver Diseases, ARBs should be avoided in patients with cirrhosis.[25]
Renal impairment: No dose adjustment of candesartan is required for creatinine clearance greater than 30 mL/min. Dose reduction and monitoring of renal function and electrolytes should be considered when creatinine clearance is less than 30 mL/min. The American Diabetes Association recommends titrating ARBs to the maximum tolerated dose to prevent the progression of chronic kidney disease and decrease cardiovascular events in nonpregnant individuals with diabetes mellitus and hypertension.[19]
Pregnancy considerations: The American College of Obstetricians and Gynecologists advises against using ARBs, including candesartan, during pregnancy due to the risks of fetal growth restriction and malformations such as renal dysgenesis and calvarial hypoplasia.[26] Labetalol, methyldopa, and long-acting nifedipine are preferred alternatives for hypertension in pregnancy.[27]
The fetal renin–angiotensin–aldosterone system plays a vital role in nephrogenesis and circulatory homeostasis. ARBs block angiotensin II type 1 receptors, thereby suppressing aldosterone and reducing renal perfusion in both the mother and the fetus, contributing to teratogenesis. Women of reproductive potential should be counseled about pregnancy risks before initiation and advised to use effective contraception.
Breastfeeding considerations: The excretion of candesartan in human milk is currently unknown. However, study results have shown the presence of candesartan in rat milk. Although preliminary evidence suggests that candesartan passes into breast milk in small amounts and is minimally detectable in the plasma of breastfed infants, there is potential for severe adverse reactions. According to the product label, breastfeeding is not recommended while undergoing candesartan treatment.
Children: The FDA has not approved candesartan for use in infants younger than 12 months. Dosing recommendations for children aged 12 months or older are mentioned above.
Older adults: The pharmacokinetics of candesartan were assessed in older patients, especially those aged 65 or older. The study results showed pharmacokinetic linearity, with minimal accumulation of candesartan observed with once-daily administration. Therefore, no dosage adjustment of candesartan is necessary.
Adverse Effects
The most common adverse effects reported for candesartan include symptomatic hypotension, abnormal renal function, and hyperkalemia. In the CHARM trial, symptomatic hypotension, impaired renal function (elevated serum creatinine), and hyperkalemia occurred with an incidence of 18.8%, 12.5%, and 6.3%, respectively. Hypotension is more common in patients who are volume- or salt-depleted due to dietary restriction, dialysis, diarrhea, emesis, or diuretic use.[6] Other reported adverse effects include headache, back pain, angioedema, and upper respiratory tract infections. A case of candesartan-induced lichenoid drug eruption has been reported.[15]
Drug-Drug Interactions
- Concurrent use of candesartan with spironolactone, potassium supplements, or other drugs that increase serum potassium levels may increase the risk of hyperkalemia. Regular monitoring of serum potassium is advised in these conditions.[28][29]
- Concurrent use of lithium and ARBs, including candesartan, may increase serum lithium concentrations and the risk of lithium toxicity. Serum lithium level monitoring is recommended.[29]
- Coadministration of nonsteroidal anti-inflammatory drugs with candesartan, including selective cyclooxygenase 2 inhibitors, may decrease renal function and oppose the antihypertensive effect of ARBs. Periodic monitoring of renal function is recommended for patients receiving concomitant therapy.[30]
- Combination blockade of the renin-angiotensin system with ARBs, ACE inhibitors, or aliskiren increases the risk of hypotension, hyperkalemia, and renal dysfunction, including acute kidney injury. Combination treatment with candesartan, ACE inhibitors, or mineralocorticoid receptor antagonists is not recommended.[31]
- Concomitant administration of candesartan and clarithromycin is associated with an increased risk of hyperkalemia and acute kidney injury compared to azithromycin, likely due to the inhibition of hepatic organic anion-transporting polypeptides by clarithromycin. This interaction is more pronounced in patients with renal impairment, warranting caution when prescribing clarithromycin with candesartan, but further research is required.[32]
Contraindications
The major contraindication to candesartan is hypersensitivity to the medication or excipients. Candesartan-induced angiodema has been reported.[33] Concomitant use of candesartan with aliskiren is contraindicated in patients with diabetes mellitus. The Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE) trial was terminated early due to higher rates of renal dysfunction, hyperkalemia, and hypotension in patients taking aliskiren with ACE inhibitors or ARBs.[34]
Boxed Warnings
Candesartan is considered a teratogen and has an FDA-issued boxed warning for fetal toxicity. Medications that interfere with the renin-angiotensin-aldosterone system diminish fetal renal function if used in the second or third trimesters of pregnancy. The risk of fetal morbidity and mortality increases due to oligohydramnios caused by reduced renal function. Affected neonates may present with skull hypoplasia, lung hypoplasia, hypotension, renal failure, and death.[35][36]
Warnings and Precautions
- Pediatric patients: Candesartan should not be administered to infants younger than 12 months due to adverse effects on developing kidneys.
- Symptomatic hypotension: Symptomatic hypotension may occur, particularly in patients with volume depletion; a dose reduction of candesartan may be required. Clinicians should also adjust diuretic doses and consider volume repletion. Blood pressure monitoring is advised during dose escalation and during major surgical procedures or anesthesia. Intravenous fluids and vasopressors may be required in cases of severe hypotension.[37]
- Nephrotoxicity: Renal function should be regularly monitored in patients receiving candesartan because drugs that inhibit the renin-angiotensin system can cause renal insufficiency. Candesartan may need to be discontinued if a significant decline in renal function is observed. The initiation of ARBs may increase serum creatinine levels, particularly in patients with extensive atherosclerotic cardiovascular disease. Elevations in serum creatinine levels could be due to bilateral renal artery stenosis or unilateral renal artery stenosis in patients with a solitary functioning kidney. Serum creatinine increases of greater than 30% from baseline warrant evaluation for bilateral renal artery stenosis.[38]
- Angioedema: Patients with a history of angioedema from an ACE inhibitor can receive an ARB beginning 6 weeks after the ACE inhibitor is discontinued. This decision should be made after a rigorous risk-benefit evaluation and patient education regarding recurrence risk.[4][39]
Monitoring
Patients receiving candesartan should undergo regular blood pressure monitoring to assess response to the medication. Additionally, clinicians should monitor for symptomatic hypotension, which may present with dizziness, lightheadedness, nausea, syncope, and fatigue.[40] Additionally, ejection fraction and volume status should be monitored closely in patients with congestive heart failure receiving candesartan.[7] Because hyperkalemia and impaired renal function can occur with candesartan use, serum potassium and renal function should be closely monitored.[41]
Toxicity
Signs and Symptoms of Overdose
Candesartan overdose manifests with symptomatic hypotension, dizziness, and reflex tachycardia. Patients who develop symptomatic hypotension should have their vital signs monitored closely. Unintentional overdoses in children have also been reported.[42]
Management of Overdose
Patients should be placed in a supine position with their legs elevated to improve venous return. If this intervention is ineffective, clinicians can initiate fluid resuscitation and supportive pharmacotherapy to increase blood pressure.[40] Furthermore, when an overdose involves the candesartan-hydrochlorothiazide combination, clinicians should also evaluate for hydrochlorothiazide toxicity. Hydrochlorothiazide overdose, characterized by hypokalemia, hyponatremia, dehydration, and metabolic alkalosis, can worsen hypotension and electrolyte disturbances. While addressing an overdose of candesartan, clinicians must consider the possibilities of multiple-drug overdoses, drug-drug interactions, and altered pharmacokinetics.[43] Consultation with a medical toxicologist or the National Poison Control Center for the most recent information is recommended in a complex overdose.
Enhancing Healthcare Team Outcomes
Candesartan is an antihypertensive agent commonly used to manage congestive heart failure.[7] Therefore, the cardiologist or heart failure specialist should be consulted to optimize guideline-directed medical therapy. Pharmacists should review potential drug-drug interactions, conduct medication reconciliation, and notify prescribers of any discrepancies. Nurses should monitor vital signs, assess volume status, and educate patients on the importance of adhering to treatment.
Angioedema associated with candesartan requires rapid stabilization by emergency clinicians.[39] Severe cases may require admission to the medical intensive care unit under the supervision of a critical care clinician. A medical toxicologist or poison control center should be consulted for a candesartan overdose. If an overdose is intentional, a psychiatric consultation is indicated after medical stabilization.
Results from a recent study investigating the potential advantages of clinician-pharmacist collaborative drug therapy management for pediatric hypertension showed higher rates of achieving target blood pressure levels without significantly increasing adverse events.[44] The entire interprofessional healthcare team, including clinicians, specialists, nursing staff, and pharmacists, plays a vital role in optimizing candesartan therapy by collaboratively monitoring treatment, ensuring accurate dosing, counseling patients, mitigating drug-drug interactions, and minimizing adverse effects to achieve optimal patient outcomes.
References
Gohlke P, Jürgensen T, von Kügelgen S, Unger T. Candesartan cilexetil: development and preclinical studies. Drugs of today (Barcelona, Spain : 1998). 1999 Feb:35(2):105-15 [PubMed PMID: 12973413]
Zhao D, Liu H, Dong P. A Meta-analysis of antihypertensive effect of telmisartan versus candesartan in patients with essential hypertension. Clinical and experimental hypertension (New York, N.Y. : 1993). 2019:41(1):75-79. doi: 10.1080/10641963.2018.1445750. Epub 2018 Mar 28 [PubMed PMID: 29589977]
Level 1 (high-level) evidenceSever P. Candesartan cilexetil: a new, long-acting, effective angiotensin II type 1 receptor blocker. Journal of human hypertension. 1997 Sep:11 Suppl 2():S91-5 [PubMed PMID: 9331018]
Jones DW, Ferdinand KC, Taler SJ, Johnson HM, Shimbo D, Abdalla M, Altieri MM, Bansal N, Bello NA, Bress AP, Carter J, Cohen JB, Collins KJ, Commodore-Mensah Y, Davis LL, Egan B, Khan SS, Lloyd-Jones DM, Melnyk BM, Mistry EA, Ogunniyi MO, Schott SL, Smith SC Jr, Talbot AW, Vongpatanasin W, Watson KE, Whelton PK, Williamson JD, Peer Review Committee Members. 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Journal of the American College of Cardiology. 2025 Nov 4:86(18):1567-1678. doi: 10.1016/j.jacc.2025.05.007. Epub 2025 Aug 14 [PubMed PMID: 40815242]
Level 1 (high-level) evidenceHosaka M, Metoki H, Satoh M, Ohkubo T, Asayama K, Kikuya M, Inoue R, Obara T, Hirose T, Imai Y, J-HOME-CARD Study Group. Randomized trial comparing the velocities of the antihypertensive effects on home blood pressure of candesartan and candesartan with hydrochlorothiazide. Hypertension research : official journal of the Japanese Society of Hypertension. 2015 Oct:38(10):701-7. doi: 10.1038/hr.2015.64. Epub 2015 Jun 4 [PubMed PMID: 26041602]
Level 1 (high-level) evidenceLund LH, Claggett B, Liu J, Lam CS, Jhund PS, Rosano GM, Swedberg K, Yusuf S, Granger CB, Pfeffer MA, McMurray JJV, Solomon SD. Heart failure with mid-range ejection fraction in CHARM: characteristics, outcomes and effect of candesartan across the entire ejection fraction spectrum. European journal of heart failure. 2018 Aug:20(8):1230-1239. doi: 10.1002/ejhf.1149. Epub 2018 Feb 12 [PubMed PMID: 29431256]
Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, Deswal A, Drazner MH, Dunlay SM, Evers LR, Fang JC, Fedson SE, Fonarow GC, Hayek SS, Hernandez AF, Khazanie P, Kittleson MM, Lee CS, Link MS, Milano CA, Nnacheta LC, Sandhu AT, Stevenson LW, Vardeny O, Vest AR, Yancy CW, ACC/AHA Joint Committee Members. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022 May 3:145(18):e895-e1032. doi: 10.1161/CIR.0000000000001063. Epub 2022 Apr 1 [PubMed PMID: 35363499]
Level 1 (high-level) evidenceKaul S. Evidentiary Landscape of Heart Failure Therapies, Regulatory Decisions, and Translation Into Guidelines. Journal of the American College of Cardiology. 2025 Aug 26:86(8):610-624. doi: 10.1016/j.jacc.2025.06.036. Epub [PubMed PMID: 40835369]
Kittleson MM, Panjrath GS, Amancherla K, Davis LL, Deswal A, Dixon DL, Januzzi JL Jr, Yancy CW. 2023 ACC Expert Consensus Decision Pathway on Management of Heart Failure With Preserved Ejection Fraction: A Report of the American College of Cardiology Solution Set Oversight Committee. Journal of the American College of Cardiology. 2023 May 9:81(18):1835-1878. doi: 10.1016/j.jacc.2023.03.393. Epub 2023 Apr 19 [PubMed PMID: 37137593]
Level 3 (low-level) evidenceKjeldsen SE, von Lueder TG, Smiseth OA, Wachtell K, Mistry N, Westheim AS, Hopper I, Julius S, Pitt B, Reid CM, Devereux RB, Zannad F. Medical Therapies for Heart Failure With Preserved Ejection Fraction. Hypertension (Dallas, Tex. : 1979). 2020 Jan:75(1):23-32. doi: 10.1161/HYPERTENSIONAHA.119.14057. Epub 2019 Dec 2 [PubMed PMID: 31786973]
Fu H, Hosomi N, Pelisch N, Nakano D, Liu G, Ueno M, Miki T, Masugata H, Sueda Y, Itano T, Matsumoto M, Nishiyama A, Kohno M. Therapeutic effects of postischemic treatment with hypotensive doses of an angiotensin II receptor blocker on transient focal cerebral ischemia. Journal of hypertension. 2011 Nov:29(11):2210-9. doi: 10.1097/HJH.0b013e32834bbb30. Epub [PubMed PMID: 21934531]
Level 3 (low-level) evidenceTakao T, Horino T, Kagawa T, Matsumoto R, Shimamura Y, Ogata K, Inoue K, Taniguchi Y, Taguchi T, Morita T, Terada Y. Possible involvement of intracellular angiotensin II receptor in high-glucose-induced damage in renal proximal tubular cells. Journal of nephrology. 2011 Mar-Apr:24(2):218-24 [PubMed PMID: 20890878]
Wang Z, Niu Q, Peng X, Li M, Liu K, Liu Y, Liu J, Jin F, Li X, Wei Y. Candesartan cilexetil attenuated cardiac remodeling by improving expression and function of mitofusin 2 in SHR. International journal of cardiology. 2016 Jul 1:214():348-57. doi: 10.1016/j.ijcard.2016.04.007. Epub 2016 Apr 5 [PubMed PMID: 27085127]
Fehér G, Pusch G. [Role of antihypertensive drugs in the treatment of migraine]. Orvosi hetilap. 2015 Feb 1:156(5):179-85. doi: 10.1556/OH.2015.30056. Epub [PubMed PMID: 25618859]
Iijima K, Mima Y. Candesartan-Associated Lichenoid Drug Eruption. Cureus. 2025 Jun:17(6):e85920. doi: 10.7759/cureus.85920. Epub 2025 Jun 13 [PubMed PMID: 40656380]
Naoe EEL, Tabuzo MMB, Jamora RDG. Candesartan for Treatment of Migraine Headache: A Scoping Review. Clinical therapeutics. 2025 Sep:47(9):807-812. doi: 10.1016/j.clinthera.2025.06.003. Epub 2025 Jun 25 [PubMed PMID: 40571531]
Level 2 (mid-level) evidenceAilani J, Burch RC, Robbins MS, Board of Directors of the American Headache Society. The American Headache Society Consensus Statement: Update on integrating new migraine treatments into clinical practice. Headache. 2021 Jul:61(7):1021-1039. doi: 10.1111/head.14153. Epub 2021 Jun 23 [PubMed PMID: 34160823]
Level 3 (low-level) evidenceElSayed NA, Aleppo G, Aroda VR, Bannuru RR, Brown FM, Bruemmer D, Collins BS, Hilliard ME, Isaacs D, Johnson EL, Kahan S, Khunti K, Leon J, Lyons SK, Perry ML, Prahalad P, Pratley RE, Seley JJ, Stanton RC, Gabbay RA, on behalf of the American Diabetes Association. 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes-2023. Diabetes care. 2023 Jan 1:46(Suppl 1):S191-S202. doi: 10.2337/dc23-S011. Epub [PubMed PMID: 36507634]
American Diabetes Association Professional Practice Committee. 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes-2025. Diabetes care. 2025 Jan 1:48(1 Suppl 1):S239-S251. doi: 10.2337/dc25-S011. Epub [PubMed PMID: 39651975]
Rao SV, O'Donoghue ML, Ruel M, Rab T, Tamis-Holland JE, Alexander JH, Baber U, Baker H, Cohen MG, Cruz-Ruiz M, Davis LL, de Lemos JA, DeWald TA, Elgendy IY, Feldman DN, Goyal A, Isiadinso I, Menon V, Morrow DA, Mukherjee D, Platz E, Promes SB, Sandner S, Sandoval Y, Schunder R, Shah B, Stopyra JP, Talbot AW, Taub PR, Williams MS. 2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2025 Apr:151(13):e771-e862. doi: 10.1161/CIR.0000000000001309. Epub 2025 Feb 27 [PubMed PMID: 40014670]
Level 1 (high-level) evidence. Candesartan. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. 2012:(): [PubMed PMID: 31643728]
Kassem I, Sanche S, Li J, Bonnefois G, Dubé MP, Rouleau JL, Tardif JC, White M, Turgeon J, Nekka F, de Denus S. Population Pharmacokinetics of Candesartan in Patients with Chronic Heart Failure. Clinical and translational science. 2021 Jan:14(1):194-203. doi: 10.1111/cts.12842. Epub 2020 Aug 28 [PubMed PMID: 32702160]
Sommerfeldt J, Sartorius H, von Sarnowski B, Klein S, Ritter CA. Drug administration via feeding tubes-a procedure that carries risks: systematic identification of critical factors based on commonly administered drugs in a cohort of stroke patients. European journal of clinical pharmacology. 2024 Nov:80(11):1599-1623. doi: 10.1007/s00228-024-03723-4. Epub 2024 Jul 29 [PubMed PMID: 39073438]
Level 1 (high-level) evidenceCarey RM, Moran AE, Whelton PK. Treatment of Hypertension: A Review. JAMA. 2022 Nov 8:328(18):1849-1861. doi: 10.1001/jama.2022.19590. Epub [PubMed PMID: 36346411]
Biggins SW, Angeli P, Garcia-Tsao G, Ginès P, Ling SC, Nadim MK, Wong F, Kim WR. Diagnosis, Evaluation, and Management of Ascites, Spontaneous Bacterial Peritonitis and Hepatorenal Syndrome: 2021 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology (Baltimore, Md.). 2021 Aug:74(2):1014-1048. doi: 10.1002/hep.31884. Epub [PubMed PMID: 33942342]
American College of Obstetricians and Gynecologists' Committee on Practice Bulletins—Obstetrics. ACOG Practice Bulletin No. 203: Chronic Hypertension in Pregnancy. Obstetrics and gynecology. 2019 Jan:133(1):e26-e50. doi: 10.1097/AOG.0000000000003020. Epub [PubMed PMID: 30575676]
Easterling T, Mundle S, Bracken H, Parvekar S, Mool S, Magee LA, von Dadelszen P, Shochet T, Winikoff B. Oral antihypertensive regimens (nifedipine retard, labetalol, and methyldopa) for management of severe hypertension in pregnancy: an open-label, randomised controlled trial. Lancet (London, England). 2019 Sep 21:394(10203):1011-1021. doi: 10.1016/S0140-6736(19)31282-6. Epub 2019 Aug 1 [PubMed PMID: 31378394]
Level 1 (high-level) evidenceFujii H, Nakahama H, Yoshihara F, Nakamura S, Inenaga T, Kawano Y. Life-threatening hyperkalemia during a combined therapy with the angiotensin receptor blocker candesartan and spironolactone. The Kobe journal of medical sciences. 2005:51(1-2):1-6 [PubMed PMID: 16199929]
Level 3 (low-level) evidenceZwanzger P, Marcuse A, Boerner RJ, Walther A, Rupprecht R. Lithium intoxication after administration of AT1 blockers. The Journal of clinical psychiatry. 2001 Mar:62(3):208-9 [PubMed PMID: 11305712]
Level 3 (low-level) evidenceFournier JP, Sommet A, Bourrel R, Oustric S, Pathak A, Lapeyre-Mestre M, Montastruc JL. Non-steroidal anti-inflammatory drugs (NSAIDs) and hypertension treatment intensification: a population-based cohort study. European journal of clinical pharmacology. 2012 Nov:68(11):1533-40. doi: 10.1007/s00228-012-1283-9. Epub 2012 Apr 15 [PubMed PMID: 22527348]
Level 2 (mid-level) evidenceWhitlock R, Leon SJ, Manacsa H, Askin N, Rigatto C, Fatoba ST, Farag YMK, Tangri N. The association between dual RAAS inhibition and risk of acute kidney injury and hyperkalemia in patients with diabetic kidney disease: a systematic review and meta-analysis. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association. 2023 Oct 31:38(11):2503-2516. doi: 10.1093/ndt/gfad101. Epub [PubMed PMID: 37309038]
Level 1 (high-level) evidenceTonial NC, Bota SE, Kang Y, Muanda FT, Urquhart BL, Weir MA. Adverse events with co-prescription of angiotensin receptor blockers and clarithromycin compared to azithromycin: A population-based retrospective cohort study. Pharmacotherapy. 2025 Jul:45(7):414-425. doi: 10.1002/phar.70032. Epub 2025 Jul 17 [PubMed PMID: 40671487]
Level 2 (mid-level) evidenceRasmussen ER, Hallberg P, Baranova EV, Eriksson N, Karawajczyk M, Johansson C, Cavalli M, Maroteau C, Veluchamy A, Islander G, Hugosson S, Terreehorst I, Asselbergs FW, Norling P, Johansson HE, Kohnke H, Syvänen AC, Siddiqui MK, Lang CC, Magnusson PKE, Yue QY, Wadelius C, von Buchwald C, Bygum A, Alfirevic A, Maitland-van der Zee AH, Palmer CNA, Wadelius M. Genome-wide association study of angioedema induced by angiotensin-converting enzyme inhibitor and angiotensin receptor blocker treatment. The pharmacogenomics journal. 2020 Dec:20(6):770-783. doi: 10.1038/s41397-020-0165-2. Epub 2020 Feb 21 [PubMed PMID: 32080354]
Parving HH, Brenner BM, McMurray JJ, de Zeeuw D, Haffner SM, Solomon SD, Chaturvedi N, Persson F, Desai AS, Nicolaides M, Richard A, Xiang Z, Brunel P, Pfeffer MA, ALTITUDE Investigators. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. The New England journal of medicine. 2012 Dec 6:367(23):2204-13. doi: 10.1056/NEJMoa1208799. Epub 2012 Nov 3 [PubMed PMID: 23121378]
Level 1 (high-level) evidenceKorkes H, Oliveira LG, Berlinck L, Borges AF, Goes FS, Watanabe S, Landman C, Sass N. PP138. Human fetal malformations associated with the use of angiotensin II receptor antagonist. Pregnancy hypertension. 2012 Jul:2(3):314-5. doi: 10.1016/j.preghy.2012.04.249. Epub 2012 Jun 13 [PubMed PMID: 26105460]
Hünseler C, Paneitz A, Friedrich D, Lindner U, Oberthuer A, Körber F, Schmitt K, Welzing L, Müller A, Herkenrath P, Hoppe B, Gortner L, Roth B, Kattner E, Schaible T. Angiotensin II receptor blocker induced fetopathy: 7 cases. Klinische Padiatrie. 2011 Jan:223(1):10-4. doi: 10.1055/s-0030-1269895. Epub 2011 Jan 26 [PubMed PMID: 21271514]
Level 3 (low-level) evidenceShibata S, Matsunaga M, Oikawa M, Nitahara K, Higa K. [Severe hypotension after induction of general anesthesia in a patient receiving an angiotensin II receptor antagonist and an alpha-blocker]. Masui. The Japanese journal of anesthesiology. 2005 Jun:54(6):670-2 [PubMed PMID: 15966388]
Level 3 (low-level) evidenceKidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2020 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. Kidney international. 2020 Oct:98(4S):S1-S115. doi: 10.1016/j.kint.2020.06.019. Epub [PubMed PMID: 32998798]
Level 1 (high-level) evidenceHaymore BR, Yoon J, Mikita CP, Klote MM, DeZee KJ. Risk of angioedema with angiotensin receptor blockers in patients with prior angioedema associated with angiotensin-converting enzyme inhibitors: a meta-analysis. Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology. 2008 Nov:101(5):495-9. doi: 10.1016/S1081-1206(10)60288-8. Epub [PubMed PMID: 19055203]
Level 1 (high-level) evidencePrasa D, Hoffmann-Walbeck P, Barth S, Stedtler U, Ceschi A, Färber E, Genser D, Seidel C, Deters M. Angiotensin II antagonists - an assessment of their acute toxicity. Clinical toxicology (Philadelphia, Pa.). 2013 Jun:51(5):429-34. doi: 10.3109/15563650.2013.800875. Epub 2013 May 22 [PubMed PMID: 23692319]
Level 2 (mid-level) evidenceDesai AS, Swedberg K, McMurray JJ, Granger CB, Yusuf S, Young JB, Dunlap ME, Solomon SD, Hainer JW, Olofsson B, Michelson EL, Pfeffer MA, CHARM Program Investigators. Incidence and predictors of hyperkalemia in patients with heart failure: an analysis of the CHARM Program. Journal of the American College of Cardiology. 2007 Nov 13:50(20):1959-66 [PubMed PMID: 17996561]
Level 2 (mid-level) evidenceHetterich N, Lauterbach E, Stürer A, Weilemann LS, Lauterbach M. Toxicity of antihypertensives in unintentional poisoning of young children. The Journal of emergency medicine. 2014 Aug:47(2):155-62. doi: 10.1016/j.jemermed.2014.02.006. Epub 2014 Apr 18 [PubMed PMID: 24746907]
Level 2 (mid-level) evidenceXie M, Tang T, Liang H. Efficacy of single-pill combination in uncontrolled essential hypertension: A systematic review and network meta-analysis. Clinical cardiology. 2023 Aug:46(8):886-898. doi: 10.1002/clc.24082. Epub 2023 Jul 11 [PubMed PMID: 37432701]
Level 1 (high-level) evidenceDonald BJ, King TD, Phillips BL, Jones K, Barham A, Watson J, Batson J. Physician-Pharmacist Collaborative Drug Therapy Management in Pediatric Hypertension. The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG. 2023:28(3):204-211. doi: 10.5863/1551-6776-28.3.204. Epub 2023 Jun 2 [PubMed PMID: 37303761]